Page 53 - Read Online
P. 53

Anugwom et al. Hepatoma Res 2022;8:7  https://dx.doi.org/10.20517/2394-5079.2021.123  Page 13 of 13

                   carcinoma before liver transplant: a cohort study and literature review. Front Immunol 2021;12:653437.  DOI  PubMed  PMC
               74.      DeLeon TT, Salomao MA, Aqel BA, et al. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver
                   transplantation: the Mayo Clinic experience. J Gastrointest Oncol 2018;9:1054-62.  DOI  PubMed  PMC
               75.      Dueland S, Guren TK, Boberg KM, et al. Acute liver graft rejection after ipilimumab therapy. Ann Oncol 2017;28:2619-20.  DOI
                   PubMed
               76.      Herbaux C, Gauthier J, Brice P, et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin
                   lymphoma. Blood 2017;129:2471-8.  DOI  PubMed
               77.      Lechler RI, Sykes M, Thomson AW, Turka LA. Organ transplantation--how much of the promise has been realized? Nat Med
                   2005;11:605-13.  DOI
               78.      Lei H, Reinke P, Volk HD, Lv Y, Wu R. Mechanisms of immune tolerance in liver transplantation-crosstalk between alloreactive T
                   cells and liver cells with therapeutic prospects. Front Immunol 2019;10:2667.  DOI  PubMed  PMC
               79.      Du X, Chang S, Guo W, Zhang S, Chen ZK. Progress in liver transplant tolerance and tolerance-inducing cellular therapies. Front
                   Immunol 2020;11:1326.  DOI  PubMed  PMC
               80.      Varkaris A, Lewis DW, Nugent FW. Preserved liver transplant after PD-1 pathway inhibitor for hepatocellular carcinoma. Am J
                   Gastroenterol 2017;112:1895-6.  DOI  PubMed
               81.      Hua H, Kong Q, Zhang H, Wang J, Luo T, Jiang Y. Targeting mTOR for cancer therapy. J Hematol Oncol 2019;12:71.  DOI  PubMed
                   PMC
               82.      Zheng Y, Jiang Y. mTOR inhibitors at a glance. Mol Cell Pharmacol 2015;7:15-20.  PubMed  PMC
               83.      Tsung I, Worden FP, Fontana RJ. A pilot study of checkpoint inhibitors in solid organ transplant recipients with metastatic cutaneous
                   squamous cell carcinoma. Oncologist 2021;26:133-8.  DOI  PubMed  PMC
               84.      Rao RD, Buckner JC, Sarkaria JN. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. Curr Cancer Drug
                   Targets 2004;4:621-35.  DOI  PubMed
               85.      Smedman TM, Line PD, Guren TK, Dueland S. Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant
                   recipients. Acta Oncol 2018;57:1414-8.  DOI  PubMed
               86.      Nguyen  LS,  Ortuno  S,  Lebrun-Vignes  B,  et  al.  Transplant  rejections  associated  with  immune  checkpoint  inhibitors:  a
                   pharmacovigilance study and systematic literature review. Eur J Cancer 2021;148:36-47.  DOI  PubMed
               87.      Kittai AS, Oldham H, Cetnar J, Taylor M. Immune checkpoint inhibitors in organ transplant patients. J Immunother 2017;40:277-81.
                   DOI  PubMed
               88.      Ros J, Matos I, Martin-Liberal J. Immunotherapy in organ-transplanted cancer patients: efficacy and risk of organ rejection. Ann Oncol
                   2019;30:1173-7.  DOI  PubMed
               89.      Tanaka K, Albin MJ, Yuan X, et al. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft
                   rejection. J Immunol 2007;179:5204-10.  DOI  PubMed  PMC
               90.      Au KP, Chok KSH. Immunotherapy after liver transplantation: where are we now? World J Gastrointest Surg 2021;13:1267-78.  DOI
                   PubMed  PMC
               91.      Gao H, Li K, Tu H, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer
                   Res 2014;20:6418-28.  DOI  PubMed
               92.      Jiang Z, Jiang X, Chen S, et al. Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of
                   hepatocellular carcinoma. Front Immunol 2016;7:690.  DOI  PubMed  PMC
               93.      Tan AT, Yang N, Lee Krishnamoorthy T, et al. Use of expression profiles of HBV-DNA integrated into genomes of hepatocellular
                   carcinoma cells to select T cells for immunotherapy. Gastroenterology 2019;156:1862-76.e9.  DOI  PubMed
               94.      Hafezi M, Tan A, Bertoletti A. Personalized armored TCR-redirected T cell therapy for liver/organ transplant with recurrent cancer.
                   Cells 2021;10:1861.  DOI  PubMed  PMC
               95.      Qasim W, Brunetto M, Gehring AJ, et al. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells,
                   targeting HBsAg in a liver transplant patient. J Hepatol 2015;62:486-91.  DOI  PubMed
               96.      Tagliamonte M, Petrizzo A, Mauriello A, Tornesello ML, Buonaguro FM, Buonaguro L. Potentiating cancer vaccine efficacy in liver
                   cancer. Oncoimmunology 2018;7:e1488564.  DOI  PubMed  PMC
               97.      Mizukoshi E, Nakamoto Y, Tsuji H, Yamashita T, Kaneko S. Identification of alpha-fetoprotein-derived peptides recognized by
                   cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma. Int J Cancer 2006;118:1194-204.  DOI  PubMed
               98.      Samson A, Bentham MJ, Scott K, et al. Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver
                   cancer. Gut 2018;67:562-73.  DOI  PubMed  PMC
   48   49   50   51   52   53   54   55   56   57   58